placebo, aspirine, clopidogrel — Competitive Intelligence Brief

placebo, aspirine, clopidogrel (placebo, aspirine, clopidogrel) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agents. Area: Cardiovascular.

marketed Antiplatelet agents Cyclooxygenase (aspirin); P2Y12 receptor (clopidogrel) Cardiovascular Small molecule

Target snapshot

placebo, aspirine, clopidogrel (placebo, aspirine, clopidogrel) — University Hospital, Angers. This is a combination study comparing placebo, aspirin (a non-selective cyclooxygenase inhibitor), and clopidogrel (a P2Y12 platelet receptor antagonist) for antiplatelet effects.

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
placebo, aspirine, clopidogrel TARGET	placebo, aspirine, clopidogrel	University Hospital, Angers	marketed	Antiplatelet agents	Cyclooxygenase (aspirin); P2Y12 receptor (clopidogrel)
Blinded clopidogrel	Blinded clopidogrel	VA Office of Research and Development	marketed	Antiplatelet agents	P2Y12 receptor
Aspirin or thienopyridine	Aspirin or thienopyridine	Associations for Establishment of Evidence in Interventions	marketed	Antiplatelet agents	COX-1 (aspirin); P2Y12 receptor (thienopyridines)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agents class)

1. Associations for Establishment of Evidence in Interventions · 1 drug in this class
2. University Hospital, Angers · 1 drug in this class
3. VA Office of Research and Development · 1 drug in this class